KRONOS BIO ($KRON) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $2,509,200 and earnings of -$0.26 per share.
You can see Quiver Quantitative's $KRON stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KRONOS BIO Hedge Fund Activity
We have seen 21 institutional investors add shares of KRONOS BIO stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARTNERS CAPITAL INVESTMENT GROUP, LLP removed 1,084,012 shares (-67.3%) from their portfolio in Q4 2024, for an estimated $1,029,811
- MARINER, LLC removed 1,041,031 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,040,926
- TANG CAPITAL MANAGEMENT LLC added 1,003,382 shares (+inf%) to their portfolio in Q4 2024, for an estimated $953,212
- ARTAL GROUP S.A. removed 842,954 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $842,869
- ACUITAS INVESTMENTS, LLC removed 554,500 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $526,775
- MILLENNIUM MANAGEMENT LLC removed 329,302 shares (-16.1%) from their portfolio in Q4 2024, for an estimated $312,836
- PRIVIUM FUND MANAGEMENT (UK) LTD removed 292,182 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $292,152
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
